BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 20060421)

  • 1. Strategies for development of Dengue virus inhibitors.
    Noble CG; Chen YL; Dong H; Gu F; Lim SP; Schul W; Wang QY; Shi PY
    Antiviral Res; 2010 Mar; 85(3):450-62. PubMed ID: 20060421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ten years of dengue drug discovery: progress and prospects.
    Lim SP; Wang QY; Noble CG; Chen YL; Dong H; Zou B; Yokokawa F; Nilar S; Smith P; Beer D; Lescar J; Shi PY
    Antiviral Res; 2013 Nov; 100(2):500-19. PubMed ID: 24076358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses.
    Kampmann T; Yennamalli R; Campbell P; Stoermer MJ; Fairlie DP; Kobe B; Young PR
    Antiviral Res; 2009 Dec; 84(3):234-41. PubMed ID: 19781577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Narasin, a novel antiviral compound that blocks dengue virus protein expression.
    Low JS; Wu KX; Chen KC; Ng MM; Chu JJ
    Antivir Ther; 2011; 16(8):1203-18. PubMed ID: 22155902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A high-throughput assay using dengue-1 virus-like particles for drug discovery.
    Qing M; Liu W; Yuan Z; Gu F; Shi PY
    Antiviral Res; 2010 May; 86(2):163-71. PubMed ID: 20153777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule drug discovery for Dengue and West Nile viruses: applying experience from hepatitis C virus.
    Parkinson T; Pryde DC
    Future Med Chem; 2010 Jul; 2(7):1181-203. PubMed ID: 21426163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3',5'Di-O-trityluridine inhibits in vitro flavivirus replication.
    De Burghgraeve T; Selisko B; Kaptein S; Chatelain G; Leyssen P; Debing Y; Jacobs M; Van Aerschot A; Canard B; Neyts J
    Antiviral Res; 2013 May; 98(2):242-7. PubMed ID: 23470860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell.
    Talarico LB; Pujol CA; Zibetti RG; Faría PC; Noseda MD; Duarte ME; Damonte EB
    Antiviral Res; 2005 Jun; 66(2-3):103-10. PubMed ID: 15911027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dengue Virus Reporter Replicon is a Valuable Tool for Antiviral Drug Discovery and Analysis of Virus Replication Mechanisms.
    Kato F; Hishiki T
    Viruses; 2016 May; 8(5):. PubMed ID: 27164125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of an efficient dengue virus replicon for development of assays of discovery of small molecules against dengue virus.
    Yang CC; Tsai MH; Hu HS; Pu SY; Wu RH; Wu SH; Lin HM; Song JS; Chao YS; Yueh A
    Antiviral Res; 2013 May; 98(2):228-41. PubMed ID: 23499649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach.
    Melino S; Paci M
    FEBS J; 2007 Jun; 274(12):2986-3002. PubMed ID: 17509079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Dengue virus helicase and methyltransferase as targets for fragment-based drug discovery.
    Coutard B; Decroly E; Li C; Sharff A; Lescar J; Bricogne G; Barral K
    Antiviral Res; 2014 Jun; 106():61-70. PubMed ID: 24704437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide inhibitors against dengue virus infection.
    Panya A; Bangphoomi K; Choowongkomon K; Yenchitsomanus PT
    Chem Biol Drug Des; 2014 Aug; 84(2):148-57. PubMed ID: 24612829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a small-molecule inhibitor of dengue virus using a replicon system.
    Hsu YC; Chen NC; Chen PC; Wang CC; Cheng WC; Wu HN
    Arch Virol; 2012 Apr; 157(4):681-8. PubMed ID: 22249364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The flavivirus polymerase as a target for drug discovery.
    Malet H; Massé N; Selisko B; Romette JL; Alvarez K; Guillemot JC; Tolou H; Yap TL; Vasudevan S; Lescar J; Canard B
    Antiviral Res; 2008 Oct; 80(1):23-35. PubMed ID: 18611413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dengue drug discovery: Progress, challenges and outlook.
    Lim SP
    Antiviral Res; 2019 Mar; 163():156-178. PubMed ID: 30597183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and characterization of a stable luciferase dengue virus for high-throughput screening.
    Zou G; Xu HY; Qing M; Wang QY; Shi PY
    Antiviral Res; 2011 Jul; 91(1):11-9. PubMed ID: 21575658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule inhibitor discovery for dengue virus protease using high-throughput screening.
    Manzano M; Padia J; Padmanabhan R
    Methods Mol Biol; 2014; 1138():331-44. PubMed ID: 24696346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target.
    Lescar J; Luo D; Xu T; Sampath A; Lim SP; Canard B; Vasudevan SG
    Antiviral Res; 2008 Nov; 80(2):94-101. PubMed ID: 18674567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of novel antivirals against flaviviruses.
    Patkar CG; Kuhn RJ
    Novartis Found Symp; 2006; 277():41-52; discussion 52-6, 71-3, 251-3. PubMed ID: 17319153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.